Navigation Links
BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer
Date:3/30/2009

SAN DIEGO, March 30 /PRNewswire/ -- BrainCells Inc. (BCI), a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of neurologic conditions, announced today the appointment of Dr. Philip Jochelson as chief medical officer and Jason Levin as chief business officer. Both have extensive experience in the biopharmaceutical industry with specific expertise in building neurology assets for success. The two will serve in integral roles managing clinical programs and licensing/partnership agreements for BrainCells' pipeline of neurologic compounds.

"We have two compounds in Phase 2 trials which will produce the first ever data on clinical impact from targeting neurogenesis for therapeutic benefit," said Jim Schoeneck, BrainCells CEO. "We have confidence in our drug candidates based on what we know about their neurogenic properties from our platform that enables us to conduct comparison analysis between multiple compounds, experiment with various pathways, analyze complex pharmacology, and image and measure the neurogenic process. Philip and Jason are top caliber people that come at a pivotal time in the company's development."

Dr. Jochelson will replace Steve Targum as chief medical officer. His primary focus will be on progression of the company's clinical programs and expansion of the pipeline into broader indications. Dr. Jochelson was most recently senior vice president of development and chief medical officer at Somaxon, a neurology and psychiatry-focused specialty pharmaceutical company, where he was responsible for the development of all product candidates while also supporting financing and business development activities. Prior to that, he was at Neurocrine Biosciences where he led several clinical development programs. Through his combined experience, he has designed and implemented multiple clinical studies across all phases of development, and has progressed three compounds from Phase 1 to NDA submission. Dr. Jochelson previously held positions in clinical development at Boehringer Ingelheim and Alliance Pharmaceutical Corp. He graduated from Medical School in South Africa and is a licensed physician in California.

Mr. Levin will be responsible for all strategic business development activities including licensing, acquisitions and partnering. He joins BrainCells with more than 15 years of experience in the life science industry, most recently as vice president of corporate development at Jazz Pharmaceuticals, a neurology and psychiatry-focused specialty pharmaceutical company, where he was responsible for licensing, acquisitions, corporate strategy and strategic alliances. Prior to Jazz Pharmaceuticals, he was director of business development at ALZA Corporation, a wholly owned subsidiary of Johnson and Johnson, where he was responsible for both in- and out-licensing of the company's drug delivery technology. Mr. Levin received an M.B.A. from the University of Texas, McCombs Graduate School of Business, has been a member of the Licensing Executive Society since 2000 and serves as an advisor to several early stage biopharmaceutical companies.

About BrainCells Inc.

BrainCells Inc. (BCI) is a drug discovery and development company leading the scientific research of neurogenesis by applying its robust and proprietary platform technology to identify novel pathways for small molecule therapeutics to treat various neurologic conditions. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictive screening platform, BCI can direct the selection and development of neurogenic compounds, increasing the opportunity for successful clinical trials in a variety of neurological indications. For more information, visit http://www.braincellsinc.com.

    Contact:
    Kim Richards
    Porter Novelli Life Sciences
    619-849-5377
    krichards@pnlifesciences.com


'/>"/>
SOURCE BrainCells Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
2. BrainCells Inc. Expands Series B Financing to $50 Million
3. REVISED: BrainCells Inc. Expands Series B Financing to $50 Million
4. BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
5. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
6. Codexis Appoints Singapore Laboratories Managing Director
7. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
11. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Calif. , June 23, 2016  The Prostate Cancer Foundation ... increasingly precise treatments and faster cures for prostate cancer. Members of the Class ... across 15 countries. Read More About the Class of ... ... ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):